Showing results (31-40 of 50) with videos related to
Sort By:
Pageof 5
Haematologica|June 27, 2020
<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitorAidan G Gilmartin, Arthur Groy, Elizabeth R Gore, et al.Nature Structural & Molecular Biology|June 18, 2021
Dnmt1 has de novo activity targeted to transposable elementsChuck Haggerty, Helene Kretzmer, Christina Riemenschneider, et al.Journal of Biomolecular Screening|August 21, 2012
Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screensElsie Diaz, Carl A Machutta, Stephanie Chen, et al.Proceedings of the National Academy of Sciences of the United States of America|February 11, 2012
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)Michael T McCabe, Alan P Graves, Gopinath Ganji, et al.Cancer Cell|June 13, 2018
CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal HematopoiesisSarah M Greenblatt, Na Man, Pierre-Jacques Hamard, et al.Nature|October 12, 2012
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsMichael T McCabe, Heidi M Ott, Gopinath Ganji, et al.Scientific Reports|December 23, 2017
Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple MyelomaAllison E Drew, Oscar Moradei, Suzanne L Jacques, et al.The Journal of Biological Chemistry|July 18, 2021
GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in miceAndrew C Pearce, Mark J Bamford, Ruth Barber, et al.Journal of Medicinal Chemistry|July 13, 2021
Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) InhibitorsJonathan T Seal, Stephen J Atkinson, Paul Bamborough, et al.Cancer Discovery|July 5, 2022
PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral MimicryAmish J Patel, Sarah Warda, Jesper L V Maag, et al.Pageof 5